عنوان

Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents :

شابک

1461316057

شابک

9781461316053

شماره

b536092

عنوان اصلي

Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents :

نام عام مواد

[Book]

ساير اطلاعات عنواني

Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 & 28, 1988

نام نخستين پديدآور

edited by Joel Morganroth, E. Neil Moore.

محل نشرو پخش و غیره

Boston, MA

نام ناشر، پخش کننده و غيره

Springer US

تاریخ نشرو بخش و غیره

1989

نام خاص و کميت اثر

(316 pages).

عنوان فروست

Developments in cardiovascular medicine, 100.

متن يادداشت

I. Thrombolytic Agents: Clinical Trials ISSUES --;1. Measurement of infarct size: effect of reperfusion with arterial blood --;2. Pitfalls in the design and evaluation of clinical trials of intravenously administered cardiovascular drugs --;3. The relative benefit and risks of intravenous streptokinase and tissue plasminogen activator in acute myocardial infarction --;4. New agents and new insights for thrombolytic therapy in acute myocardial infarction: focus on anistreplase, urokinase, and prourokinase --;5. Myocardial reperfusion: Role of adjunctive agents to improve reperfusion and prevent reperfusion injury --;Panel Discussion --;II. Thrombolytic Agents: Adjunctive Issues --;6. Interactions between thrombolysis and sudden cardiac death --;7. What are the overall strategies for post-thrombolytic care that include use of angioplasty? --;8. Thrombolytic agents: biologic properties and issues regarding products derived by recombinant DNA technology --;Panel Discussion --;III. Risk vs. Benefit for Antiarrhythmic Drugs --;9. What do new anti-arrhythmic agents have to show to establish a favorable risk versus benefit ratio? --;10. What do new cardiovascular agents (e.g. antiarrhythmic drugs) have to show to establish a favorable risk versus benefit ratio to obtain approvability? --;clinical viewpoint --;11. Is it practical to develop a class III antiarrhythmic agent? --;Panel Discussion --;IV. Hypolipidemic Agents: Clinical & Regulatory Issues --;12. What are the recommendations to the medical community to institute hypolipidemic therapy? --;13. What are the comparative risks versus benefits for bile acid sequestrants, HMG CO-A reductase inhibitors, nicotinic acid, probucol, and fibric acid derivatives? --;14. What levels of cholesterol should be studied and what should be the study designs? --;15. Should a change in the atherosclerotic process be required for approval of new hypolipidemic agents? --;16. How and when should long-term safety data be obtained for hypolipidemic agents? --;17. What is required to gain approval of lipid altering drugs? --;Panel Discussion --;Participant List.

متن يادداشت

Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 and 28, 1988

عنوان اصلي به زبان ديگر

Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 and 28, 1988

موضوع مستند نشده

Cardiology.

موضوع مستند نشده

Health & Biological Sciences.

موضوع مستند نشده

Medicine.

شماره رده

نشانه اثر

مستند نام اشخاص تاييد نشده

edited by Joel Morganroth, E. Neil Moore.

مستند نام اشخاص تاييد نشده

E Neil Moore

مستند نام اشخاص تاييد نشده

Joel Morganroth

نام الکترونيکي

نوع ماده

[Book]

تكميل شده

Y